{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:02:31Z","timestamp":1791838951338,"version":"4.3.4"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Published literature has raised concerns regarding a causal association between glucagon\u2010like peptide 1 receptor agonist (GLP\u20101RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP\u20101RA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Our evaluation included data from (i) 93 liraglutide or semaglutide phase 2 and 3 clinical trials, of which six were cardiovascular outcome trials (CVOTs); (ii) post\u2010marketing surveillance from the Novo Nordisk safety database (evaluating data for liraglutide and semaglutide); and (iii) the US Merative\u2122 MarketScan\u00ae Commercial Database. Hazard ratios (HRs) were estimated for overall thyroid cancer risk for treatment groups in the clinical trials and for individuals with type 2 diabetes treated with any GLP\u20101RAs versus sodium\u2013glucose cotransporter\u20102 inhibitors (SGLT2is) for the real\u2010world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from all clinical trials across 101\u2009732 participants (totalling 206\u2009950 patient\u2010years of exposure [PYE]) reported low numbers of thyroid cancer events; across all trials, HRs were 1.70 (95% confidence interval [CI] 0.99, 3.03) and 1.83 (0.70, 6.71) for pooled GLP\u20101RA versus pooled placebo and active comparator, respectively. For CVOTs, the HR (95% CI) for pooled GLP\u20101RA versus pooled placebo was 1.41 (0.72, 2.81). Post\u2010marketing surveillance data showed a low thyroid cancer reporting rate of 0.001 cases\/100 PYE and did not support an association between liraglutide or semaglutide exposure and the number of thyroid cancer events. Analysis of the US Merative\u2122 MarketScan\u00ae Commercial Database reported an HR of 0.87 (95% CI 0.58, 1.29) for the occurrence of thyroid cancer in individuals using any GLP\u20101RAs versus SGLT2is.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The totality of data analysed did not suggest an association between liraglutide or semaglutide use and thyroid cancer risk in adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70291","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:06:37Z","timestamp":1764057997000},"page":"1499-1507","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of thyroid cancer risk associated with glucagon\u2010like peptide 1 receptor agonist use"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-6787","authenticated-orcid":false,"given":"Tina","family":"Vilsb\u00f8ll","sequence":"first","affiliation":[{"name":"Clinical Research, Steno Diabetes Center Copenhagen University of Copenhagen  Herlev Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stellfeld","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Division of Endocrinology Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sune","family":"Dandanell","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens\u2010Peter","family":"David","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyda T. P.","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Heged\u00fcs","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Odense University Hospital University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01668-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97233"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.113"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13437"},{"key":"e_1_2_9_11_1","first-page":"25","article-title":"Lixisenatide as add\u2010on therapy to basal insulin","volume":"8","author":"Brown DX","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2028"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038679"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16147"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16504"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16489"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13597"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15292"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078225"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0387"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0105"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2025.05.016"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0154"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S305496"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2021.1955255"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148"},{"key":"e_1_2_9_29_1","unstructured":"Merative MarketScan.Merative MarketScan Research Databases.2025. Accessed March 19 2025.https:\/\/www.merative.com\/documents\/merative-marketscan-research-databases"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","unstructured":"SenaA GilbertJ RaoG SchuemieM.CohortGenerator: Cohort Generation for the OMOP Common Data Model.2024. Accessed March 19 2025.https:\/\/ohdsi.github.io\/CohortGenerator\/","DOI":"10.32614\/CRAN.package.CohortGenerator"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2259-3"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0026"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000437263"},{"key":"e_1_2_9_35_1","unstructured":"SchuemieM SuchardM.SqlRender: Rendering Parameterized SQL and Translation to Dialects.2024. Accessed March 19 2025.https:\/\/ohdsi.github.io\/SqlRender\/"},{"key":"e_1_2_9_36_1","unstructured":"RaoG SchuemieM GilbertJ.ROhdsiWebApi: Interacting With an OHDSI WebApi Instance.2023. Accessed March 19 2025.https:\/\/ohdsi.github.io\/ROhdsiWebApi\/"},{"key":"e_1_2_9_37_1","unstructured":"SchuemieM SuchardM RyanP.CohortMethod: New\u2010User Cohort Method with Large Scale Propensity and Outcome Models.2024. Accessed March 19 2025.https:\/\/ohdsi.github.io\/CohortMethod\/"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae613"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.4852"},{"key":"e_1_2_9_45_1","first-page":"455","article-title":"Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients","volume":"65","author":"Elbasan O","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031116"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7030037"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098135"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.4236\/ijohns.2019.86024"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925377"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13259"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70291","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:48:11Z","timestamp":1769719691000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/dom.70291"],"URL":"https:\/\/doi.org\/10.1111\/dom.70291","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70291\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70291\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70291\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70291\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70291\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"2025-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}